DOCSLIB.ORG

Annual Report 2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annual Report 2 Draft as of December 20. PDF version for illustrative purposes, report will be published online. ANNUAL REPORT 2 Key Figures for 2019 MERCK GROUP Key figures Change € million 2019 2018 € million % Net sales 16,152 14,836 1,315 8.9% Operating result (EBIT)1 2,120 1,727 393 22.8% Margin (% of net sales)1 13.1% 11.6% EBITDA1 4,066 3,528 539 15.3% Margin (% of net sales)1 25.2% 23.8% EBITDA pre1 4,385 3,800 585 15.4% Margin (% of net sales)1 27.1% 25.6% Profit after tax 1,324 3,396 -2,072 -61.0% Earnings per share (in €) 3.04 7.76 -4.72 -60.8% Earnings per share pre (€)1 5.56 5.10 0.46 9.0% Business free cash flow1 2,732 2,508 224 8.9% 1Not defined by International Financial Reporting Standards (IFRSs). MERCK GROUP MERCK GROUP Net sales EBITDA pre1 € million € million 1 Not defined y International Financial Reporting Standards (IFRSs). Owing to the altered expectations in terms of the impact of the Covid-19 pandemic, some chapters of this Annual Report were updated on May 12, 2020. The respective text passages are marked in magenta. Table of Contents Annual Report To Our Shareholders Corporate Governance 5 Letter from Stefan Oschmann 136 Capital Structure and Corporate Bodies of Merck KGaA 8 The Executive Board 137 Statement on Corporate Governance including Compensation Report 9 Merck Shares 167 Report of the Supervisory Board 170 Objectives of the Supervisory Board with respect to Its Composition and Profile of Skills and Expertise Combined Consolidated Management Report Financial Statements 12 Fundamental Information about the 174 Consolidated Income Statement Group 175 Consolidated Statement of Comprehensive Income 12 Merck 176 Consolidated Balance Sheet 20 Strategy 177 Consolidated Cash Flow Statement 27 Internal Management System 178 Consolidated Statement of Changes in Net Equity 33 Corporate Responsibility 180 Notes 44 Research and Development 180 General Disclosures 56 People at Merck 185 Group Structure 64 Report on Economic Position 194 Performance Indicators 64 Macroeconomic and Sector-Specific 200 Operating Activities Environment 213 Operating Assets, Liabilities, and Contingent Liabilities 67 Review of Forecast against Actual Business Developments 240 Employees 75 Course of Business and Economic Position 249 Capital Structure, Investments, and Financing Activities 75 Merck Group 287 Other Disclosures 87 Healthcare 294 Scope of Consolidation 93 Life Science 98 Performance Materials 103 Corporate and Other 104 Report on Risks and Opportunities 120 Report on Expected Developments 125 Report in accordance with Section 315a 306 Responsibility Statement (1) of the German Commercial Code 307 Independent Auditor´s Report (HGB) 127 Additional Information on Merck KGaA 314 Business Development 2015 – 2019 in accordance with the German Commercial Code (HGB) 315 Financial Calendar TO OUR SHAREHOLDERS 5 Letter from Stefan Oschmann 8 The Executive Board 9 Merck Shares Letter from Stefan Oschmann Letter from Stefan Oschmann To our Shareholders ___ Letter from Stefan Oschmann 5 In this Annual Report, you will find all the relevant information about Merck and its performance in fiscal 2019. For the first time, we are publishing our Annual Report exclusively online and have streamlined it in comparison with previous years. As you can see, we are focusing on the essentials here, too. From my perspective, the major topics of 2019 included the debate on the role of companies in society – in other words, their purpose. I am very pleased to note that while economic growth and profitability are and will always remain important and, of course, essential, more and more companies are realizing that these are not the only factors that matter. Companies must always create value for society as well. This is crucial to long-term success, and in my view, a pivotal element of good corporate citizenship. We are curious minds dedicated to human progress. That is our purpose, and what drives us at Merck. And not only since the latest debates on the role of companies in society. Everything at Merck revolves around science. For 352 years, it has been at the heart of everything we do. Science enables us to develop new technologies needed, for instance, to treat serious diseases, to help researchers worldwide develop new therapies, and to shape the digital revolution. We have therefore clearly articulated our ambition in our Group strategy: We want to become the vibrant science and technology company. In other words, we want to rank among the scientific and technological leaders in all three of our business sectors. We also aim to outperform our competitors in terms of both sales growth and margin growth so as to continue to generate sustainable value for our owners. Our agenda is ambitious and challenging, but it is also feasible. In 2019, we reached many milestones, as the following examples show: By acquiring Versum Materials and Intermolecular, we are now well-positioned to become a leading supplier in the electronic materials market and to further drive future innovations in this field. It is clear that the global volume of data is going to grow exponentially in the coming years. In 2018, it amounted to around 33 zettabytes – in megabytes, that is a number with 15 zeros. By 2025, that figure could grow to 175 zettabytes. All these data must be generated, processed, transferred, and stored. This is a veritable technological challenge and a major opportunity for Merck: We produce leading-edge materials used in almost all the latest electronic devices. Our research results in Healthcare are very encouraging – and we have a promising pipeline. The U.S. Food and Drug Administration approved our medicine Mavenclad® in the United States for the treatment of certain forms of multiple sclerosis – a great achievement for Merck. Bavencio®, our immuno-oncology therapy, was approved in the United States, Europe, Japan and other markets for the treatment of patients with advanced renal cell carcinoma in combination with another drug. In addition, we formed a global strategic alliance with GlaxoSmithKline to further advance the development of our novel investigational therapy, bintrafusp alfa, in the fight against hard-to-treat forms of cancer. Moreover, we presented positive results for evobrutinib in relapsing multiple sclerosis (MS). We also made progress on our genome-editing technologies. Our portfolio for CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) genome scissors is used to understand the functions of individual genes and their interaction in a cell. Last year, we received further patents in this key area and now hold a total of 22 patents for CRISPR technology worldwide. In addition, we entered into an agreement with the Broad Institute of MIT and Harvard in the United States to offer non-exclusive licenses to CRISPR intellectual property under our respective control. Through this agreement, we are simplifying the path to licensing CRISPR technology in order to make it more widely available to the global research and discovery community. To our Shareholders ___ Letter from Stefan Oschmann 6 Stefan Oschmann, Chairman of the Executive Board and CEO As you can see, we made excellent progress in all three of our business sectors last year. And we grew profitably. At € 16.2 billion, Group sales rose by 8.9% in comparison with 2018. EBITDA pre, the most important financial indicator we use to steer our operating business, amounted to € 4.4 billion, a year-on-year increase of 15.4%. Earnings per share pre (EPS pre increased by 9% to € 5.56. Our strong business development in 2019 was only possible thanks to the untiring engagement of our approximately 57,000 employees worldwide. On behalf of the entire Executive Board, I would like to warmly thank all our people for their tremendous commitment. As shareholders, you are benefiting from our good business performance in 2019. Last year, the Merck share price rose by 17%. For fiscal 2019, we will propose to the Annual General Meeting the payment of a dividend of € 1.30 per share. In 2020, we plan to build on the good development achieved in 2019 and to continue to grow profitably. We will move forward with our strategy of profitable growth while focusing, as we always do, on reducing our debt, which rose significantly owing to our most recent major acquisition of Versum Materials. As of the end of 2019, our net financial debt totaled € 12.4 billion. That is why we will now be setting our sights on growing organically and generating high cash flow. At the same time, we will work to sustainably strengthen a culture of cost awareness throughout Merck. In our Healthcare business sector, we will continue to deliver profitable growth in our core business, especially in emerging markets, with a special focus on China. We want to fully leverage the potential of our new medicines Mavenclad® and Bavencio® and to forge ahead with our promising pipeline projects. In Life Science, we are aiming to expand our leading positions in bioprocessing and e-commerce. In addition, we will continue to unlock new growth opportunities through our Promise Ventures in gene editing and novel modalities, end-to-end bioprocessing solutions, and connected labs. Within Performance Materials, we will work to further reap the benefits of Bright Future, our five-year transformation program, as well as to successfully integrate Versum Materials and Intermolecular. We see particularly attractive long-term growth potential for Performance Materials in the businesses with materials and solutions for the semiconductor industry and OLEDs (organic light emitting diodes. Overall, we are also keeping a close eye on the geopolitical and trade policy conflicts currently underway, as they are also likely to influence our businesses. Yet, irrespective of this, Merck can achieve great things in 2020 and beyond.
Load more

Recommended publications
  • Biomarin Pharmaceutical Inc
    BIOMARIN PHARMACEUTICAL INC FORM 10-K (Annual Report) Filed 03/02/15 for the Period Ending 12/31/14 Address 105 DIGITAL DRIVE NOVATO, CA 94949 Telephone 4155066700 CIK 0001048477 Symbol BMRN SIC Code 2834 - Pharmaceutical Preparations Industry Biotechnology & Drugs Sector Healthcare Fiscal Year 12/31 http://www.edgar-online.com © Copyright 2015, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use. f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 Or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-26727 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 68 -0397820 (State of other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 770 Lindaro Street San Rafael, California 94901 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (415) 506-6700 Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Name of Each Exchange on Which Registered Common Stock, $.001 par value The NASDAQ Global Select Market Securities registered under Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
    [Show full text]
  • Q2 2010 Half-Year Financial Report Worldreginfo - C49e8129-Cd51-43E5-Af66-E15ec3c851f8 2
    Q2 2010 Half-Year Financial Report WorldReginfo - c49e8129-cd51-43e5-af66-e15ec3c851f8 2 CONTENTS 3 Half-Year Management Report of the Merck Group as of June 30, 2010 3 At a glance | Highlights 4 Merck Group 8 Merck shares 9 Business sectors 11 Divisions 11 Merck Serono 13 Consumer Health Care 15 Liquid Crystals 16 Performance & Life Science Chemicals 17 Merck Millipore 18 Corporate and Other 18 Risk Report 19 Report on Expected Developments 20 Half-Year Consolidated Financial Statements as of June 30, 2010 31 Responsibility Statement 32 Executive Board | Supervisory Board | Capital structure 33 Financial calendar for 2010 | Publication contributors Cover photo: Automated distribution of miniscule particles onto microtiter plates. These are used to synthesize compound libraries for ultra-high-throughput screening in drug discovery research. WorldReginfo - c49e8129-cd51-43e5-af66-e15ec3c851f8 Half-Year Management Report of the Merck Group as of June 30, 2010 3 At a glance | Highlights AT A glaNCE Key figures – 2nd quarter 2010 Pharma­ Corporate Change EUR million ceuticals Chemicals and Other Total in % Total revenues 1,564.4 643.6 – 2,208.0 15.6 Gross margin 1,297.2 393.5 – 1,690.8 21.5 Research and development –302.2 –36.5 –0.1 –338.8 –0.5 Operating result 158.2 166.0 2.0 326.2 76.8 Exceptional items – – –1.2 –1.2 – Earnings before interest and tax (EBIT) 158.2 166.0 0.8 325.0 76.2 EBIT before depreciation and amortization (EBITDA) 350.0 208.6 1.3 559.9 38.4 Return on sales in % (ROS: operating result/total revenues) 10.1 25.8 – 14.8
    [Show full text]
  • Unity: Concern Over Patent Licensing Draft .•.....• 1 Proposal on Cancelling Door-To-Door Sales Deals •....•
    • Issue No. 421 Report No. 311, February 11, 1977 IN THIS ISSUE page Connnunity: Concern over Patent Licensing Draft .•.....• 1 Proposal on Cancelling Door-to-Door Sales Deals •....•. 2 Briefs: Court of Auditors; Fishing Licenses .•...•....• 3 Italy: 'Social Pact' Skirts Wage Cost Issue •........•. 3 Ireland: Budget Raises Speculation on Elections ....... 4 Britain: Modest Upturn Inspires Hopes, Caution ........ S France: Employers Want Shift in Social Cost Burden ..•. 6 Germany: Labor Costs Now Higher Than in USA .•.•••••••• 7 Euro Company Scene •••......•.....•.••..•.•..•....•. , •. 7 &unity: The European Connnission is going to great lengths to alle­ Business Fears viate the concern of the European business connnunity, es­ over Patent pecially in Germany and the U.K., over a preliminary draft Licensing Draft regulation that would exempt en bloc from the Article 85(1) ban any licensing agreements containing certain restrictive clauses. The Connnission and national experts were sched­ uled to discuss the document again this month, before in­ viting connnents from national business associations. In the meantime, however, Brussels has been taken by surprise by the publication of the confidential preliminary draft in a respected German financial newspaper. Connnission offi­ cials are now trying to counter criticism of business rep­ resentatives, who have described the draft as being "too narrowly conceived, contradictory, and impractical." The regulation would relieve the parties both from no­ tifying the Connnission and from applying for an exemption for a restrictive licensing agreement (as they are required to do now) if the latter meets the criteria set out in the draft regulation. A block exemption would greatly ease the Connnission's work load because the applications for exemp­ tions have been piling up by the tens of thousands.
    [Show full text]
  • The Resiliency Compass: Navigating Global Value Chain Disruption in an Age of Uncertainty
    In Collaboration with Kearney The Resiliency Compass: Navigating Global Value Chain Disruption in an Age of Uncertainty WHITE PAPER JULY 2021 Images: Getty Images, Unsplash Contents Foreword 3 Executive summary 4 1 Disruption drives a rethink 5 2 Resilience in action 8 2.1 Getting to grips with disruption 8 2.2 Introducing the resiliency compass 8 2.3 Who are the resilience leaders? 10 3 Setting the right course with the resiliency compass 11 4 Call for action: global coordination for the long term 14 Methodology 15 Contributors 16 Acknowledgements 17 Endnotes 19 © 2021 World Economic Forum. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, including photocopying and recording, or by any information storage and retrieval system. The Resiliency Compass: Navigating Global Value Chain Disruption in an Age of Uncertainty 2 July 2021 The Resiliency Compass: Navigating Global Value Chain Disruption in an Age of Uncertainty Foreword Unlocking the future of cooperation, resilience and prosperity for global value chains. Francisco Betti Per Kristian Hong Head of Shaping the Future of Managing Director and Advanced Manufacturing and Partner, Strategic Operations Production, Member of the and World Economic Forum Executive Committee, World Relationship Lead, Kearney Economic Forum COVID-19 has kept manufacturing companies systems if both the global economy and companies beyond busy for many months and the challenges are to successfully navigate future disruptions that are far from over, from ensuring safety and may affect global value chains. security on the shop floor and facing supply and demand disruptions to accelerating digital In 2020, the World Economic Forum, in transformation and reskilling to build resilience.
    [Show full text]
  • Disclaimerthis Is a Publication of a Third Party
    DisclaimerThis is a publication of a third party. Merck KGaA, Darmstadt, Germany is not responsible for its content. Whenever this document refers to Merck it refers to Merck KGaA, Darmstadt, Germany or the group of companies affiliated with Merck KGaA, Darmstadt, Germany. In the United States and Canada the group of companies affiliated with Merck KGaA, Darmstadt, Germany operates under individual business names (EMD Serono, MilliporeSigma, EMD Performance Materials). 2 November 2018 Corporates Merck KGaA Merck KGaAGermany, Chemicals/Pharmaceuticals STABLE Germany, Chemicals/Pharmaceuticals A- Corporate profile Ratings & Outlook Merck KGaA is a diversified chemicals/pharmaceuticals group that was founded in 1668 Corporate Ratings A-/Stable with the opening of a Merck pharmacy in Darmstadt, Germany, where the group is still Short Term Rating S-1/Stable based. The Merck family holds 70% of the voting rights with the remainder in public ownership. After several acquisitions and divestments, the group now consists of three divisions: healthcare (pharmaceuticals and consumer healthcare), life science and Analysts performance materials (centred on its global market leadership in liquid crystals). In 2015, Olaf Tölke Merck acquired the US-based life science company Sigma Aldrich for a price of +49 69 6677389 11 USD 17bn and became one of the consolidators in that industry. In pharmaceuticals, it is [email protected] a specialised, mid-sized producer of drugs, relying on two blockbuster products, Erbitux and Rebif, but has developed a new focus on immuno-oncological products, mainly Related methodology represented by its antibody avelumab. At the end of 2014, US-based big pharma Corporate Rating Methodology, company Pfizer acquired partial ownership of the molecule as well as US distribution January 2018 rights for USD 850m.
    [Show full text]
  • Reducing Prescription Drug Costs in Colorado Cost Drivers and Strategies to Address Them
    2nd Edition Reducing Prescription Drug Costs in Colorado Cost Drivers and Strategies to Address Them January 2021 Contents Forward to Reducing Prescription Drug Costs in Colorado, 2nd Edition ........... 4 2020 Updates to This Report .................................................................. 4 Executive Summary ............................................................................ 6 Introduction and Purpose ...................................................................... 6 Cost Drivers ...................................................................................... 7 Prioritized Solutions ............................................................................ 8 Learning from Medicaid Policy ............................................................... 12 The Department Invites Your Collaborative Partnership .................................. 12 Industry Trends and Background Information ............................................. 13 Prescription Drug Cost, Utilization, and Trends ........................................... 13 The U.S. Pays the Highest Prices for Pharmaceutical Drugs in the World .............. 16 Many Coloradans Aren’t Taking Their Drugs Appropriately Because They Can’t Afford Them, Often Leading to Worse Health Outcomes That Are More Costly ....... 16 Major Drivers of Prescription Drug Prices .................................................. 18 Patent Protections .............................................................................. 18 Anti-Competitive Practices and Price Fixing
    [Show full text]
  • Dr. Holger Hofmeister
    Dr. Holger Hofmeister Partner, Frankfurt Mergers and Acquisitions Dr. Holger Hofmeister advises corporate clients and private equity firms in connection with acquisitions, divestitures, public takeovers, joint ventures, and other M&A and corporate matters, including capital markets-related issues. In addition, he advises on corporate governance-related matters and corporate restructurings. Dr. Hofmeister was named in WirtschaftsWoche as one of the best corporate lawyers in Germany. In addition, he has been named by both Handelsblatt and WirtschaftsWoche as one of Germany’s top M&A advisors. He also is listed as recommended lawyer in JUVE and was listed in Best Lawyers in Germany 2021. Dr. Hofmeister’s representative matters include advising, among others: - Adevinta ASA in its US$9.2 billion acquisition of eBay Classifieds Group from eBay Inc.; T: 49.69.74220.117 - Airbnb, Inc. in its acquisition of Germany-based fewoVista S.L. & Co. KG and Vacaleo GmbH; F: 49.69.74220.417 - Apax Partners in connection with: [email protected] • its proposed US$8.5 billion bid for ISS/AS, a facilities management provider, from Goldman Sachs Capital Partners and EQT Partners AB; and Education • the US$420 million sale of Versatel AG, a provider of telecommunications and informa- Second State Exam, Appellate Court tion technology services, to Kohlberg Kravis Roberts & Co., a private equity firm; of Duesseldorf, 2001 - Black Diamond Capital Management, L.L.C., along with InvestIndustrial, in their Dr. jur., University of Regensburg, 1999 US$425 million acquisition of the phenolic specialty resin, hexamine and European forest products resins businesses of Hexion Inc.; First State Exam, University of Regensburg, 1998 - Braskem S.A.
    [Show full text]
  • Last Name First Name Job Title Company A
    Last Name First Name Job Title Company A. Jürgensen Jonas Undergrad Synapse Abel Gernot Science Manager Novozymes Abele Julia M.Sc. Julia Abele, Leibniz Institut Aiach Karen CEO Lysogene Aichinger Eric Head of Business Develop. Biotype Airey Raj Ability Pharma Ability Pharma Aldag Joern CEO Hookipa Alistar Miriam - Bioflux Ameniero Anton Pharma & Biotech Recruiter Seuss Recruitment Ameri JacQueline CEO & Co-founder PanCryos Antil Jasbir Student HTW Berlin Ateh Davidson CEO BioMoti Bach Matthias Marketing Manager BIO Deutschland Baghdassarian Sylviane Segment Marketing Manager Merck Group Bancroft Dani Freelance Journalist SynBioBeta Barthel Peter CFO Vertical Media Basu Somsuvro Post Doctoral Research Philipps-Universität Marburg Batchelor Alex CEO Orbit Discovery Ltd Belichard Pierre Co-founder & CEO Enterome Benedict Nicholas Co-Founder & CEO Allecra Therapeutics GmbH Bensimon Aaron BensimonCEO Genomic Vision Bensimon Aaron President & CEO Genomic Vision Berry David General Partner Flagship Pioneering Berti Davide Business Develop. Manager Clarivate Analytics Besse Joël Co Founder Momentum Biotech Bidani Aroussi Medical Consultant CarthaGenetics Birkegaard Hansted Alfred Collaborative Innovation Specialist Novozymes Birner Hubert General Partner TVM Capital Bit-Avragim Nana Head Digital Health & LS SingularityU Germany Summit Boglioli Elsy Partner & MD BCG Boissel François-Henri CEO & Co-founder Novadiscovery Bongartz André Associate Director Business QuintilesIMS Borghei Golnaz Associate Partner Ventac Partners Bosch Assela Business Development Manager Specipig Bothe Martin Geschäftsführer Smarterials Technology GmbH Bouchard Nico CEO Sex Positive Brand Cornelius Managing Partner INSTINCTIF Partners Braun Claire Family Labiotech.eu Bravo Marcelo CEO Oxford PharmaScience Group Plc Bruno Tiago Business Development Manager GenIbet Bungers Tobias Dipl.-Ing. BV Bungers Simon Founder & CEO labfolder Buth Ines-Regina Managing Partner akampion Cailleteau Sandrine Managing Director Reminisciences Calvo Daniel Marketing & Commun.
    [Show full text]
  • 2.2.2. List of Corporate Offices and Directorships of the Directors Exercised at 31 December 2020
    CORPORATE GOVERNANCE Composition of the Board of Directors 2.2.2. List of corporate offices and directorships of the Directors exercised at 31 December 2020 JEAN-PAUL AGON Chairman and Chief Executive Officer French Age: 64 Joined the L’Oréal Group in 1978. Following an international career as Chief Executive Officer of the Consumer Products 2 Division in Greece and of L’Oréal Paris in France, International Managing Director of Biotherm, Chief Executive Officer of L’Oréal Germany, Chief Executive Officer of the Asia Zone, Chairman and Chief Executive Officer of L’Oréal USA, Jean-Paul Agon was appointed as Deputy Chief Executive Officer of L’Oréal in 2005, and then Chief Executive Officer in April 2006 and finally Chairman and Chief Executive Officer in 2011. A Director of L’Oréal since 2006, he is also the Chairman of the Strategy and Sustainability Committee. Jean-Paul Agon is also the Chairman of the L’Oréal Corporate Foundation and Director of Air Liquide. By decision of the Board of Directors following the 2021 Annual General Meeting, Jean-Paul Agon will hold the office of Chairman of the Board of Directors without assuming the office of Chief Executive Officer as from 1 May 2021. EXPIRY DATE OF TERM OF OFFICE: 2022 ● Professional address: L’Oréal – 41, rue Martre – 92117 Clichy Cedex – France ● Holds 1,365,432 L’Oréal shares OTHER CORPORATE OFFICES AND DIRECTORSHIPS HELD French companies Air Liquide S.A.* Director Other L’Oréal Corporate Foundation Chairman of the Board L’Oréal Fund for Women Chairman of the Board Raisesherpas Director French Association of Private Enterprises (AFEP) Director French Institute of International Relations (IFRI) Director CORPORATE OFFICES AND DIRECTORSHIPS HELD OVER THE LAST FIVE YEARS AND EXPIRED None * Listed company.
    [Show full text]
  • GC Report 2011-En.Pdf
    BASF’s segments BASF in Greater China Report 2011 Chemicals Functional Solutions Content In the Chemicals segment, we supply Key data Chemicals (million €) In the Functional Solutions segment, we Key data Functional Solutions (million €) products to customers in the chemical, bundle system solutions and innovative About the report 01 Environment and safety 26 electronics, construction, textile, auto- 2011 2010 Change in % products for specific sectors and custo- 2011 2010 Change in % motive, pharmaceutical and agricultural Sales 12,958 11,377 13.9 mers, in particular for the automotive, Sales 11,361 9,703 17.1 BASF Group 02 Society 33 industries as well as many others. We chemical and construction industries. also ensure that other BASF segments EBITDA 3,188 3,000 6.3 Our portfolio comprises automotive and EBITDA 921 861 7.0 BASF in Asia Pacific 06 Recognition 38 are supplied with chemicals for produ- Income from operations industrial catalysts, automotive and Income from operations 2,441 2,302 6.0 559 467 19.7 cing downstream products. Our portfolio before special items industrial coatings and concrete admix- before special items Driving sustainability in Greater China 08 BASF in the regions 40 ranges from basic chemicals, glues and Income from operations tures as well as construction systems Income from operations 2,442 2,310 5.7 427 457 (6.6) electronic chemicals for the semicon- (EBIT) such as tile adhesives and architectural (EBIT) BASF in Greater China 10 Ten-year summary 42 ductor and solar cell industries, to coatings. solvents and plasticizers, as well as Strategic areas 14 Business contacts in Greater China 43 starting materials for detergents, 1 3 3 plastics, textile fibers, paints and Sales (%) Sales (%) Innovation 22 BASF’s segments at a glance inside front cover coatings, and pharmaceuticals.
    [Show full text]
  • Chief Technology Officer of BASF Group to Keynote the CIO Germany, Austria and Switzerland Summit
    Press Contacts: Rachel Tait Director, Client Services & Event Management CDM Media [email protected] +1 312.374.0800 Kieran Hasan Director, EMEA, CIO Summits CDM Media [email protected] +44.2920.729.275 Chief Technology Officer of BASF Group to Keynote the CIO Germany, Austria and Switzerland Summit CHICAGO, April 24, 2014 – CDM Media announced Wiebe Van Der Horst, Senior Vice President, Global Process & Enterprise Architecture, and Chief Technology Officer of the BASF Group, will be the opening keynote speaker at the second annual CIO Germany, Austria and Switzerland Summit, which will be held September 17, 2014 in Frankfurt, Germany. The CIO Germany, Austria and Switzerland Summit offers a unique platform for the DACH region’s foremost technology thinkers to collaborate on the latest industry topics and trends. The agenda’s format is designed for attending executives to discuss and share insight on the issues currently impacting CIOs in the region, while learning about the leading-edge products and services. Mr. Van Der Horst brings 20 years of experience and knowledge working in supply chain management, procurement and information systems. He will be kicking of the summit with an opening keynote presentation entitled, “From the hunted to the hunter – Transforming Information Services (IS) from reactive cost center to the proactive business enabler.” Mr. Van Der Horst will discuss how BASF has leveraged 4 key enablers (enterprise architecture, focus on end-to-end processes, change management and emerging technologies) to become a business solutions provider. “Having the BASF Group represented at the summit is outstanding, and having Wiebe Van Der Horst keynote the summit will promise for a very valuable and content-rich event,” said Kieran Hasan, Director EMEA, CIO Summits.
    [Show full text]
  • Determinationofmergern
    DETERMINATION OF MERGER NOTIFICATION M/19/011 MERCK KGAA/VERSUM MATERIALS INC. Section 21 of the Competition Act 2002 Proposed acquisition by Merck KGAA of sole control of Versum Materials, Inc. Dated 19 June 2019 Introduction 1. On 10 May 2019, in accordance with section 18(1)(a) of the Competition Act 2002, as amended (the “Act”), the Competition and Consumer Protection Commission (the “Commission”) received a notification of a proposed transaction (the “Proposed Transaction”) whereby Merck KGaA (“Merck”), through EMD Performance Materials Holding, Inc. (“EMD”), a special purpose vehicle formed specifically for the purposes of the Proposed Transaction, would acquire sole control of Versum Materials, Inc. (“Versum”). The Proposed Transaction 2. The Proposed Transaction is to be implemented by way of a merger carried out in accordance with the General Corporation Law of the State of Delaware. The terms and conditions upon which the Proposed Transaction is to take place are set out in an Agreement and Plan of Merger dated 12 April 2019 (“the Merger Agreement”) between Merck, EMD and Versum. On the basis of the Merger Agreement, the Commission considers that the undertakings involved have demonstrated a good faith intention to conclude an agreement for the purposes of section 18(1A)(b)(ii) of the Act. 3. The Proposed Transaction is conditional, amongst other things, on the approval of the Merger Agreement by a majority of the Versum shareholders. Upon closing of the Proposed Transaction, Versum will be merged with EMD which will then cease to have 1 Merger Notification No. M/19/011 Merck/Versum Materials a separate corporate existence.
    [Show full text]